Related Experiment Video

Updated: Jul 3, 2025

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.3K

Epcoritamab in B-cell malignancies: current status and prospects

Stefano Molica1, Marco Rossi2,3, David Allsup1,4

  • 1Queens Centre for Oncology and Haematology, Castle Hill Hospital, Hull University NHS Trust, Hull, UK.

Expert Opinion on Biological Therapy
|February 12, 2024
PubMed
Summary

No abstract available in PubMed .

Keywords:
Epcoritamabchronic lymphocytic leukemiadiffuse large B-cell lymphomafollicular lymphoma

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K

Related Experiment Videos

Last Updated: Jul 3, 2025

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.3K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

Articles linked to this work by shared authors, journal, and citation graph.

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.

British journal of haematology·2026

Targeted Therapies Combined with Intensive Chemotherapy in Fit Acute Myeloid Leukemia: Past Developments, Current Evidence, and Future Therapeutic Paradigms.

Journal of clinical medicine·2026

An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.

Leukemia & lymphoma·2026

Early versus Late starting of Direct Oral Anticoagulants after breakthrough ischemic stroke: A Target Trial Analysis from the ASPERA-R Study.

International journal of stroke : official journal of the International Stroke Society·2026

Long-Term Outcome of Molecularly Defined Oligodendrogliomas: Comparison of Grade 2 and 3 Tumors.

Neurology·2026

A Multipurpose Study of BaZrS3 and BaHfS3: Absolute Entropies, Thermal Decomposition, and Prediction of Intrinsic and Extrinsic Thermodynamic Stability.

The journal of physical chemistry. C, Nanomaterials and interfaces·2026

Targeting the tumor microenvironment in genitourinary cancers: current progress and future directions in prostate cancer.

Expert opinion on biological therapy·2026

Successful dose reduction of dupilumab in pediatric patients with atopic dermatitis in daily practice: results from the BioDay registry.

Expert opinion on biological therapy·2026

Potential of new BCMA-targeting therapies in overcoming resistance in multiple myeloma.

Expert opinion on biological therapy·2026

Treating Castleman disease: insights into the use and efficacy of monoclonal antibodies.

Expert opinion on biological therapy·2026

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026

Clinical characteristics, surgical management, and outcomes of uterine smooth muscle tumours of uncertain malignant potential: a single-centre experience.

Przeglad menopauzalny = Menopause review·2026

BCR-ABL1 Transcript Variants in Chronic Myeloid Leukemia Patients in Africa: A Systematic Review.

Health science reports·2026

Classical Hodgkin Lymphoma Today.

Mediterranean journal of hematology and infectious diseases·2026

Jiedu Xiaoliu formula enhances progression-free survival and immune modulation in diffuse large B-cell lymphoma: a retrospective cohort study.

Frontiers in pharmacology·2026

LTF promotes central nervous system leukemia progression via neutrophil serine proteases.

Frontiers in pharmacology·2026

Case Report: refractory hemophagocytic lymphohistiocytosis progression despite complete metabolic response in a patient with stage IV extranodal NK/T-cell lymphoma: clinical observation of "tumor-immune dissociation" phenomenon.

Frontiers in immunology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us